What is Rytary (carbidopa/levodopa extended-release)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

What is Rytary?

Rytary is an extended-release oral capsule formulation combining carbidopa and levodopa, FDA-approved for treating Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism following carbon monoxide or manganese intoxication. 1

Formulation and Mechanism

Rytary contains carbidopa-levodopa in a unique extended-release capsule design with microbeads that dissolve at different rates in the gastrointestinal tract 1. The formulation is available in four strengths:

  • 23.75 mg carbidopa/95 mg levodopa
  • 36.25 mg carbidopa/145 mg levodopa
  • 48.75 mg carbidopa/195 mg levodopa
  • 61.25 mg carbidopa/245 mg levodopa 1

The key innovation is its dual-phase release profile: it provides rapid initial absorption comparable to immediate-release carbidopa-levodopa (peak at ~1 hour), followed by sustained therapeutic levels maintained for 4-5 hours 2. This design addresses the short half-life problem of standard levodopa formulations that leads to motor fluctuations.

How It Works

Carbidopa inhibits the peripheral decarboxylation of levodopa, allowing more levodopa to cross the blood-brain barrier where it converts to dopamine 1. By blocking peripheral conversion, carbidopa reduces side effects like nausea and vomiting while making more levodopa available for the brain 1.

Clinical Advantages Over Standard Formulations

Rytary demonstrates superior pharmacokinetics compared to immediate-release formulations: it maintains more stable plasma concentrations with reduced peak-to-trough fluctuations 3, 4. In head-to-head comparisons, immediate-release carbidopa-levodopa shows peak concentrations at 1 hour that drop below 10% by 5 hours, while Rytary sustains therapeutic levels until approximately 10 hours 4.

Phase III trials showed Rytary significantly reduces daily "off-time" in advanced Parkinson's disease patients compared to immediate-release carbidopa-levodopa, without increasing troublesome dyskinesia 2. In early Parkinson's disease, it improved motor symptoms and activities of daily living compared to placebo after 30 weeks 2.

Clinical Context

While the provided guidelines [5-5] focus primarily on invasive therapies for advanced Parkinson's disease (deep brain stimulation, levodopa-carbidopa intestinal gel, apomorphine infusions), Rytary represents an oral medication option that bridges the gap between standard immediate-release formulations and more invasive continuous dopaminergic therapies. It offers extended symptom control through oral administration, making it particularly useful for patients experiencing motor fluctuations who are not yet candidates for or do not desire invasive interventions.

Common adverse events include nausea and insomnia in early Parkinson's disease patients, and falls and dyskinesia in advanced disease patients 2. The bioavailability of carbidopa from Rytary is approximately 50% relative to immediate-release tablets 1.

Related Questions

Can an adult patient with a history of Parkinson's disease take Rytary (Carbidopa and Levodopa extended release) and Carbidopa Levodopa ER (Carbidopa and Levodopa extended release) at the same time?
What are the current slow release levodopa preparations licensed by regulatory agencies, such as the Food and Drug Administration (FDA)?
Is there a pharmacokinetic interaction between Devato (levodopa/carbidopa intestinal gel) and oral minoxidil?
Can patients with Parkinson's disease who are taking Sinemet (levodopa/carbidopa) safely take iodine supplements?
Can I drink organic fruit juice while taking Sinemet (levodopa/carbidopa)?
Can intra‑articular sodium hyaluronate (Supartz) and methylprednisolone injections be given one month apart in the same knee?
In patients with localized peripheral neuropathic pain, how does a capsaicin 0.05% topical patch compare to a lidocaine 5% patch regarding indications, application, tolerability, and contraindications?
What is the appropriate treatment for otitis media with effusion (fluid behind the tympanic membrane)?
How can a one‑year‑old develop serious Pseudomonas sepsis?
Can you write a SOAP note for a 50‑year‑old female presenting for ER follow‑up of a kidney infection/UTI with severe left flank pain, difficulty ambulating, requesting a neurology referral, and include appropriate CPT and ICD‑10 codes?
How should I interpret this hormone panel for a premenopausal, non‑pregnant woman drawn in the luteal phase, and what further evaluation is recommended for the elevated DHEA‑Sulfate (DHEA‑S)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.